Analysts: This might be time for J&J to make an acquisition

03/5/2004 | Bloomberg Businessweek

The analysts point to the company's sagging stock price, a product of investor fear that Johnson & Johnson may not be able to maintain its 10% annual growth rate, as one reason the company needs to make an acquisition and get investors excited again. The analysts said the more likely targets would be in the specialty drug concerns, such as Cephalon, Allergan or Forest Labs, and St. Jude Medical on the medical device side of the industry.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Food & Beverage

Job Title Company Location
Executive Chef
Whole Foods
Bellevue, WA
Sous Chef
Sheraton
Salt Lake City, UT
Executive Chef
The Lodge & Spa at Callaway Gardens Job
Pine Mountain, GA